Myozyme and disease progression 
Myozyme and disease progression Patient Reports February 12, 2012
Myozyme Side Effects Report #6112212-X
Myozyme side effect was reported by a Physician from UNITED STATES on Feb 25, 2009. Male patient, child 9 years of age, weighting 72.53 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: disease progression, dysstasia, fatigue, movement disorder
, muscular weakness, peroneal nerve palsy, restrictive pulmonary disease. Myozyme dosage: 20 MG/KG, Q2W, INTRAVENOUS; 5 MG/KG, 2X/W, INTRAVENOUS; 10 MG/KG, QW. Patient recovered.Myozyme Side Effects Report #5679718-9
Myozyme side effect was reported by a Physician from AUSTRALIA on Mar 07, 2008. Female patient, 63 years of age, weighting 132.3 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: disease progression, pneumonia aspiration. Myozyme dosage: 20 MG/KG, Q2W, INTRAVENOUS. Patient was hospitalized. Patient recovered.
Myozyme Side Effects Report #6003463-3
Myozyme side effect was reported by a Physician from AUSTRALIA on June 03, 2008. Female patient, 63 years of age, weighting 132.3 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: disease progression, dysphagia, feeding disorder, mobility decreased, motor dysfunction, pneumonia aspiration. Myozyme dosage: 20 MG/KG, Q2W, INTRAVENOUS. Patient was hospitalized. Patient recovered.
Myozyme Side Effects Report #5901985-4
Myozyme side effect was reported by a Health Professional from UNITED STATES on Sept 15, 2008. Female patient, 46 years of age, weighting 222.7 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: disease progression, muscular weakness, urinary tract infection
. Myozyme dosage: 20 MG, Q2W, INTRAVENOUS. During the same period patient was treated with VICODIN, DARVOCET, IRON, FENUGREEK, VITAMIN. Patient recovered.Myozyme Side Effects Report #5502311-5
Myozyme side effect was reported by a Health Professional from UNITED STATES on Oct 15, 2007. Male patient, 42 years of age, weighting 152.1 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: decreased activity, disease progression, glycogen storage disease type ii, vital capacity decreased. Myozyme dosage: 20 MG/KG Q2WKS IV. During the same period patient was treated with TENORMIN, PLENDIL. Patient recovered.
Myozyme Side Effects Report #5544126-8
Myozyme side effect was reported by a Physician from UNITED STATES on Nov 23, 2007. Female patient, child 4 years of age, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: asthenia, disease progression, eyelid ptosis, ill-defined disorder. Myozyme dosage: 20 MG/KG Q2WKS, IV. Patient recovered.
Myozyme Side Effects Report #5442438-X
Myozyme side effect was reported by a Physician from UNITED STATES on Aug 16, 2007. Female patient, 34 years of age, weighting 202.8 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: disease progression, gait disturbance, glycogen storage disease type ii. Myozyme dosage: 20 MG/KG Q2WKS IV. During the same period patient was treated with ALPHA, SINGULAIR, OTHO TRICYCLEN, PAXIL. Patient recovered.
Myozyme Side Effects Report #5387617-5
Myozyme side effect was reported by a Physician from FRANCE on June 28, 2007. Female patient, child 3 years of age, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: asthenia, disease progression, glycogen storage disease type ii, respiratory tract infection, urinary retention. Myozyme dosage: 20 MG/KG Q2WS IV. Patient died on 06/01/2007.
Myozyme Side Effects Report #5409633-7
Myozyme side effect was reported by a Physician from UNITED STATES on July 30, 2007. Male patient, child 3 years of age, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: arrhythmia
, cardiac arrest , disease progression, glycogen storage disease type ii. Myozyme dosage: 40 MG/KG Q2WKS IV. During the same period patient was treated with ALPHA. Patient was hospitalized. Patient died on 07/26/2007.Myozyme Side Effects Report #5646200-4
Myozyme side effect was reported by a Physician from AUSTRALIA on Feb 20, 2008. Female patient, child 3 years of age, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: body temperature increased, convulsion, disease progression, neurological symptom. Myozyme dosage: 20 MG/KG, Q2W, INTRAVENOUS. Patient recovered.
Myozyme Side Effects Report #5942803-8
Myozyme side effect was reported by a Physician from UNITED STATES on Oct 22, 2008. Male patient, child 3 years of age, weighting 44.09 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: c-reactive protein increased, cardiac failure, cardiomegaly, dehydration, disease progression, fluid overload, hypoxic encephalopathy, leukocytosis, mental status changes. Myozyme dosage: 20 MG/KG, Q2W; INTRAVENOUS; 40 MG/KG, Q2W; INTRAVENOUS. Patient was hospitalized. Patient died on 10/24/2008.
Myozyme Side Effects Report #5988186-9
Myozyme side effect was reported by a Physician from UNITED STATES on Nov 21, 2008. Female patient, child 3 years of age, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: alopecia, blood immunoglobulin g increased, bronchial disorder, cardiac hypertrophy, cardiomyopathy
, dehydration, disease progression, foreign body trauma, pneumonia . Myozyme dosage: unknown. Patient recovered.Myozyme Side Effects Report #6046002-3
Myozyme side effect was reported by a Physician from UNITED STATES on Jan 09, 2009. Female patient, child 3 years of age, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: alopecia, cardiomyopathy
, dehydration, disease progression, foreign body trauma, infection , pneumonia , respiratory distress, respiratory failure. Myozyme dosage: 300 MG, Q2W, INTRAVENOUS. Patient recovered.Myozyme Side Effects Report #5738427-8
Myozyme side effect was reported by a Physician from UNITED STATES on Apr 30, 2008. Male patient, child 2 years of age, weighting 30.86 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: disease progression, hypokinesia, muscular weakness, nystagmus, respiratory failure. Myozyme dosage: unknown. During the same period patient was treated with ASPIRIN, COREG, LASIX, ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, RANITIDINE. Patient recovered.
Myozyme Side Effects Report #5935024-6
Myozyme side effect was reported by a Physician from ISRAEL on Oct 15, 2008. Male patient, child 2 years of age, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: cardiac hypertrophy, cardiomyopathy
, central line infection, cyanosis, deafness neurosensory, disease progression, electromyogram abnormal, hypotension, hypotonia. Myozyme dosage: 20 MG/KG, Q2W, INTRAVENOUS. During the same period patient was treated with CORTICOSTEROIDS, PHENERGAN, HYDROCORTISONE. Patient was hospitalized and became disabled. Patient recovered.Myozyme Side Effects Report #6023234-1
Myozyme side effect was reported by a Physician from ISRAEL on Dec 11, 2008. Male patient, child 2 years of age, weighting 26.46 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: acute respiratory failure, cardiac hypertrophy, cardiomyopathy
, central line infection, cough, cyanosis, deafness neurosensory, disease progression, electromyogram abnormal. Myozyme dosage: 20 MG/KG, Q2W, INTRAVENOUS. During the same period patient was treated with CORTICOSTEROIDS, PHENERGAN, HYDROCORTISONE. Patient was hospitalized and became disabled. Patient recovered.Myozyme Side Effects Report #6028578-5
Myozyme side effect was reported by a Physician from ISRAEL on Dec 22, 2008. Male patient, child 2 years of age, weighting 26.46 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: acute respiratory failure, central line infection, deafness neurosensory, disease progression, electromyogram abnormal, hypertrophic cardiomyopathy, hypotension, hypotonia, infusion related reaction. Myozyme dosage: 20 MG/KG, Q2W, INTRAVENOUS. During the same period patient was treated with CORTICOSTEROIDS, PHENERGAN, HYDROCORTISONE, ASPIRIN. Patient was hospitalized and became disabled. Patient recovered.
Myozyme Side Effects Report #5327219-X
Myozyme side effect was reported by a Physician from UNITED STATES on May 02, 2007. Female patient, child 1 years of age, weighting 20.94 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: antibody test positive, disease progression, enzyme inhibition, muscle disorder
, pyrexia. Myozyme dosage: 20 MG;KG Q2WKS IV. During the same period patient was treated with ALPHA. Patient recovered.Myozyme Side Effects Report #5375663-7
Myozyme side effect was reported by a Health Professional from UNITED STATES on June 18, 2007. Male patient, child 1 years of age, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: abasia, acute respiratory distress syndrome, aspiration, asthenia, atelectasis, condition aggravated, disease progression, disease recurrence, dysphagia. Myozyme dosage: 20 MG/KG Q2WKS; IV. During the same period patient was treated with ALPHA, CAPTOPRIL, STEROIDS. Patient was hospitalized. Patient recovered.
Myozyme Side Effects Report #5375663-7
Myozyme side effect was reported by a Health Professional from UNITED STATES on June 18, 2007. Male patient, child 1 years of age, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: abasia, acute respiratory distress syndrome, aspiration, asthenia, atelectasis, condition aggravated, disease progression, disease recurrence, dysphagia. Myozyme dosage: 20 MG/KG Q2WKS; IV. During the same period patient was treated with ALPHA, CAPTOPRIL, STEROIDS. Patient was hospitalized. Patient recovered.
Myozyme Side Effects Report #5268621-4
Myozyme side effect was reported by a Physician from BRAZIL on Feb 28, 2007. Female patient, weighting 16.31 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: bradycardia, brain oedema, cardiogenic shock, cardiomyopathy
, cyanosis, disease progression, pyrexia, tachycardia. Myozyme dosage: 20 MG/KG Q2WKS IV. During the same period patient was treated with CARVEDILOL, CAPTOPRIL. Patient died on 02/13/2007.Myozyme Side Effects Report #5272470-0
Myozyme side effect was reported by a Physician from UNITED STATES on Mar 07, 2007. Male patient was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: disease progression. Myozyme dosage: 20 MG/KG Q2WKS IV. Patient died on 03/06/2007.
Myozyme Side Effects Report #5291323-5
Myozyme side effect was reported by a Physician from BRAZIL on Mar 20, 2007. Female patient, weighting 16.31 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: bradycardia, brain herniation, brain oedema, cardiogenic shock, cyanosis, disease progression, gastrointestinal haemorrhage, haematocrit decreased, haemoglobin decreased. Myozyme dosage: 20 MG/KG Q2WKS IV. During the same period patient was treated with CARVEDILOL, CAPTOPRIL, RANITIDINE, PROTOVIT, FERROUS SULPHATE, ASCORBIC ACID, ZINC SULPHATE. Patient died on 02/13/2007.
Myozyme Side Effects Report #5293818-7
Myozyme side effect was reported by a Physician from ITALY on Mar 22, 2007. Female patient, weighting 8.11 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: disease progression. Myozyme dosage: unknown. Patient died on 02/01/2007.
Myozyme Side Effects Report #5331395-2
Myozyme side effect was reported by a Physician from UNITED STATES on May 02, 2007. Male patient was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: adhesion
, angiopathy, cardiac failure, collapse of lung, disease progression, effusion, emphysema, granulomatous liver disease. Myozyme dosage: 20 MG/KG Q2WKS IV. Patient died on 03/06/2007.Myozyme Side Effects Report #5362838-6
Myozyme side effect was reported by a Physician from UNITED STATES on June 01, 2007. Male patient, weighting 15.38 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: bacterial sepsis, central line infection, coagulopathy, diaphragmatic disorder, disease progression, enterobacter infection, heart rate increased, hypercapnia, hypotension. Myozyme dosage: 30 MG/KG Q2WKS IV. During the same period patient was treated with METHOTREXATE, RITUXIMAB, IMMUNE GLOBULIN INTRAVENOUS. Patient was hospitalized. Patient recovered.
Myozyme Side Effects Report #5160220-8
Myozyme side effect was reported by a Physician from UNITED STATES on Nov 06, 2006. Male patient was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: condition aggravated, conjunctival hyperaemia, disease progression, erythema, flushing, hypertrophic cardiomyopathy, infusion related reaction, muscular weakness, nausea
. Myozyme dosage: 20 MG/KG Q2WKS IV. Patient recovered.Myozyme Side Effects Report #5192519-3
Myozyme side effect was reported by a Physician from SAUDI ARABIA on Dec 05, 2006. Male patient, weighting 12.79 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: disease progression, respiratory distress, sepsis
. Myozyme dosage: unknown. During the same period patient was treated with ANTIBIOTIC, ANTIFUNGAL. Patient died on 07/21/2006.Myozyme Side Effects Report #5390882-1
Myozyme side effect was reported by a Health Professional from UNITED STATES on July 02, 2007. Male patient was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: abasia, aspiration, asthenia, atelectasis, blood immunoglobulin g increased, condition aggravated, disease progression, dysphagia, glycogen storage disease type ii. Myozyme dosage: 20 MG/KG Q2WKS IV. During the same period patient was treated with ALPHA, CAPTOPRIL, STEROIDS. Patient was hospitalized. Patient died on 06/30/2007.
Myozyme Side Effects Report #5404692-X
Myozyme side effect was reported by a Physician from ISRAEL on July 17, 2007. Male patient was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: disease progression, glycogen storage disease type ii. Myozyme dosage: 20 MG/KG Q2WKS IV. During the same period patient was treated with ROCEPHIN, VANCOMYCIN, FORTUM, AMIKACIN, MERONEM, LASIX. Patient died on 05/26/2007.
Myozyme Side Effects Report #5407770-4
Myozyme side effect was reported by a Physician from UNITED STATES on July 20, 2007. Male patient, weighting 12.32 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: cardiac disorder, coma, disease progression. Myozyme dosage: 17.89 MG/KG Q2WKS IV. During the same period patient was treated with DIGOXIN, DIURETICS. Patient was hospitalized. Patient died on 06/14/2007.
Myozyme Side Effects Report #5534675-0
Myozyme side effect was reported by a Physician from UNITED STATES on Nov 16, 2007. Male patient was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: aspiration, catheter related infection, cleft palate, disease progression, disease recurrence, dysphagia, nystagmus, respiratory failure. Myozyme dosage: 40 MG/KG Q2WKS IV. During the same period patient was treated with RITUXIMAB, METHOTREXATE, IMMUNE GLOBULIN INTRAVENOUS, BENADRYL, TYLENOL. Patient was hospitalized. Patient recovered.
Myozyme Side Effects Report #5637776-1
Myozyme side effect was reported by a Health Professional from UNITED STATES on Feb 07, 2008. Female patient, weighting 20.94 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: disease progression, glycogen storage disease type ii, muscular weakness, pyrexia. Myozyme dosage: 20 MG/KG, Q2W,INTRAVENOUS. Patient died on 08/30/2007.
Myozyme Side Effects Report #5659994-9
Myozyme side effect was reported by a Health Professional from UNITED STATES on Mar 03, 2008. Female patient, weighting 20.94 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: cardiopulmonary failure, disease progression, muscular weakness, no therapeutic response, pyrexia, refusal of treatment by relative. Myozyme dosage: 20 MG/KG, Q2W, INTRAVENOUS. Patient died on 08/30/2007.
Myozyme Side Effects Report #5729660-X
Myozyme side effect was reported by a Physician from ISRAEL on Apr 21, 2008. Male patient was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: cardiac hypertrophy, central line infection, cyanosis, deafness neurosensory, disease progression, dysstasia, electromyogram abnormal, hypotension. Myozyme dosage: unknown. During the same period patient was treated with CORTICOSTEROIDS, PHENERGAN, HYDROCORTISONE. Patient was hospitalized and became disabled. Patient recovered.
Myozyme Side Effects Report #5746819-6
Myozyme side effect was reported by a Physician from UNITED ARAB EMIRATES on May 04, 2008. Male patient, weighting 10.80 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: blood creatine phosphokinase increased, cardiac failure, cardio-respiratory arrest, disease progression, hypertrophic cardiomyopathy, hypotonia. Myozyme dosage: 20 MG/KG, Q2W. During the same period patient was treated with PROPRANOLOL. Patient died on 04/14/2008.
Myozyme Side Effects Report #5764034-7
Myozyme side effect was reported by a Physician from UNITED STATES on May 30, 2008. Male patient, weighting 22.05 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: cardiomyopathy
, disease progression, glycogen storage disease type ii. Myozyme dosage: 100 MG, ONCE; INTRAVENOUS. Patient died on 05/15/2008.Myozyme Side Effects Report #5768470-4
Myozyme side effect was reported by a Physician from ISRAEL on June 03, 2008. Male patient was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: cardiac hypertrophy, central line infection, cyanosis, deafness neurosensory, disease progression, electromyogram abnormal, hypotension, hypotonia. Myozyme dosage: unknown. During the same period patient was treated with CORTICOSTEROIDS, PHENERGAN, HYDROCORTISONE. Patient was hospitalized and became disabled. Patient recovered.
Myozyme Side Effects Report #5798822-8
Myozyme side effect was reported by a Physician from AUSTRALIA on June 17, 2008. Female patient, weighting 6.20 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: collapse of lung, disease progression, hypercapnia, hyperhidrosis, muscle rigidity. Myozyme dosage: 20 MG/KG, Q2W, INTRAVENOUS. During the same period patient was treated with FOLIC ACID, CAPTOPRIL, FUROSEMIDE, DIGOXIN, DOMPERIDONE, NITROFURANTOIN, FERRO. Patient recovered.
Myozyme Side Effects Report #5811792-9
Myozyme side effect was reported by a Physician from NETHERLANDS on July 03, 2008. Male patient, weighting 198.4 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: disease progression, fall
, fatigue, hypercapnia, muscular weakness. Myozyme dosage: 20 MG/KG, Q2W. During the same period patient was treated with CLEMANIL, HYDROCORTISONE. Patient recovered.Myozyme Side Effects Report #5832505-0
Myozyme side effect was reported by a Physician from AUSTRALIA on July 18, 2008. Female patient, weighting 16.53 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: collapse of lung, disease progression, hypercapnia, hyperhidrosis, muscle rigidity, upper respiratory tract infection. Myozyme dosage: 20 MG/KG, Q2W, INTRAVENOUS. During the same period patient was treated with FOLIC ACID, CAPTOPRIL, FUROSEMIDE, DIGOXIN, DOMPERIDONE, NITROFURANTOIN, FERRO. Patient died on 07/18/2008.
Myozyme Side Effects Report #5917212-8
Myozyme side effect was reported by a Consumer or non-health professional from UNITED STATES on Sept 26, 2008. Male patient was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: cardiac failure, cough, disease progression, hypoxia, irritability, nasopharyngitis, oxygen saturation decreased, rales. Myozyme dosage: 20 MG/KG, Q2W, INTRAVENOUS. Patient was hospitalized. Patient recovered.
Myozyme Side Effects Report #5927527-5
Myozyme side effect was reported by a Physician from UNITED STATES on Oct 07, 2008. Male patient was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: cardiac failure, disease progression, nasopharyngitis, refusal of treatment by relative, respiratory failure. Myozyme dosage: 20 MG/KG, Q2W, INTRAVENOUS. Patient was hospitalized. Patient died on 10/07/2008.
Myozyme Side Effects Report #6053851-4
Myozyme side effect was reported by a Physician from UNITED STATES on Jan 16, 2009. Male patient, weighting 21.83 lb, was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: alpha haemolytic streptococcal infection, aspiration, blood pressure diastolic decreased, catheter related infection, cleft palate, disease progression, dysphagia, escherichia infection, heart rate increased. Myozyme dosage: 40 MG/KG, Q2Q, INTRAVENOUS 30 MG/KG, Q2W, INTRAVENOUS, 20 MG/KG, Q2W, INTRAVENOUS. During the same period patient was treated with RITUXIMAB, METHOTREXATE, IMMUNE GLOBULIN INTRAVENOUS, BENADRYL, ACETAMINOPHEN, BUDESONIDE. Patient was hospitalized. Patient recovered.
Myozyme Side Effects Report #6130971-7
Myozyme side effect was reported by a Physician from UNITED ARAB EMIRATES on Mar 10, 2009. Male patient was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: disease progression, dysphagia, hypotonia. Myozyme dosage: 20 MG/KG, Q2W. Patient recovered.
Myozyme Side Effects Report #6137501-4
Myozyme side effect was reported by a Physician from ITALY on Mar 19, 2009. Female patient was diagnosed with glycogen storage disease type ii and was treated with Myozyme. After drug was administered, patient experienced the following side effects: disease progression, fatigue, refusal of treatment by patient, respiratory disorder. Myozyme dosage: unknown. Patient was hospitalized. Patient recovered.